TG Therapeutics, Inc. annual free cash flow for fiscal 2025 was -$25 million, an increase of 38.4% from -$41 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | ($25M) | ($41M) | ($31M) | ($176M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Free Cash Flow | ($18M) | $20M | ($23M) | $7M | ($29M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More TGTX metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS
All TGTX financial statements → Interactive TGTX charts →
About TickerBase · Data methodology & sources